

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: TMI191419

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
WILMINGTON TRUST, NATIONAL ASSOCIATION		04/23/2024	National Association : DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Company Name:</b>	Actient Pharmaceuticals LLC		
<b>Street Address:</b>	1400 Atwater Drive		
<b>City:</b>	Malvern		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19355		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>Company Name:</b>	Astora Women's Health LLC		
<b>Street Address:</b>	1400 Atwater Drive		
<b>City:</b>	Malvern		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19355		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>Company Name:</b>	Auxilium Pharmaceuticals, LLC		
<b>Street Address:</b>	1400 Atwater Drive		
<b>City:</b>	Malvern		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19355		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>Company Name:</b>	Auxilium US Holdings, LLC		
<b>Street Address:</b>	1400 Atwater Drive		
<b>City:</b>	Malvern		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19355		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>Company Name:</b>	Biospecifics Technologies Corp.		
<b>Street Address:</b>	1400 Atwater Drive		
<b>City:</b>	Malvern		

CH \$265.00.00 90552384

<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Company Name:</b>	Biospecifics Technologies LLC
<b>Street Address:</b>	1400 Atwater Drive
<b>City:</b>	Malvern
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	DAVA International, LLC
<b>Street Address:</b>	1400 Atwater Drive
<b>City:</b>	Malvern
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	DAVA Pharmaceuticals, LLC
<b>Street Address:</b>	One Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	Endo Pharmaceuticals Inc.
<b>Street Address:</b>	1400 Atwater Drive
<b>City:</b>	Malvern
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Company Name:</b>	Endo Pharmaceuticals Solutions Inc. (formerly known as Indevus Pharmaceuticals, Inc.)
<b>Street Address:</b>	1400 Atwater Drive
<b>City:</b>	Malvern
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Company Name:</b>	Generics Bidco I, LLC
<b>Street Address:</b>	One Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977

<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	Generics International (US), Inc.
<b>Street Address:</b>	One Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Corporation: NEW YORK
<b>Company Name:</b>	Par Pharmaceutical, Inc.
<b>Street Address:</b>	One Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Corporation: NEW YORK
<b>Company Name:</b>	Par Pharmaceutical Companies, Inc.
<b>Street Address:</b>	One Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Company Name:</b>	Par Sterile Products, LLC (formerly known as JHP Pharmaceuticals, LLC)
<b>Street Address:</b>	6 Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	Quartz Specialty Pharmaceuticals, LLC
<b>Street Address:</b>	One Ram Ridge Road
<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	Slate Pharmaceuticals, LLC
<b>Street Address:</b>	1400 Atwater Drive
<b>City:</b>	Malvern
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Company Name:</b>	Vintage Pharmaceuticals, LLC
<b>Street Address:</b>	One Ram Ridge Road

<b>City:</b>	Chestnut Ridge
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10977
<b>Entity Type:</b>	Limited Liability Company: DELAWARE

**PROPERTY NUMBERS Total: 10**

Property Type	Number	Word Mark
Serial Number:	90552384	ENDO THERAPEUTICS
Serial Number:	90550232	ENDO THERAPEUTICS
Serial Number:	90079215	
Serial Number:	90079225	ENDO
Serial Number:	90168104	ESR
Serial Number:	90452258	REALLY CELLULITE
Serial Number:	90168428	ENZYMATIC SUBCISION AND REMODELING (ESR)
Serial Number:	90168379	ENZYMATIC SUBCISION AND REMODELING
Serial Number:	88911832	TRUDELIVERY
Registration Number:	5307112	ENDO

**CORRESPONDENCE DATA**

**Fax Number:** 2127352000

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2127352811

**Email:** mribando@skadden.com

**Correspondent Name:** Ms. Monique L Ribando

**Address Line 1:** Skadden, Arps, Slate, Meagher & Flom LLP

**Address Line 2:** One Manhattan West

**Address Line 4:** New York, NEW YORK 10001-8602

<b>ATTORNEY DOCKET NUMBER:</b>	697130/22
<b>NAME OF SUBMITTER:</b>	MONIQUE RIBANDO
<b>SIGNATURE:</b>	MONIQUE RIBANDO
<b>DATE SIGNED:</b>	04/25/2024

**Total Attachments: 28**

source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page1.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page2.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page3.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page4.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page5.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page6.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page7.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page8.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page9.tif

source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page10.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page11.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page12.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page13.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page14.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page15.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page16.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page17.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page18.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page19.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page20.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page21.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page22.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page23.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page24.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page25.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page26.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page27.tif  
source=3 - Endo - WT - IP Release of US 2L Pledge and Security Agreement (Execution Version)#page28.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this “Release”), dated as of April 23, 2024, is made by WILMINGTON TRUST, NATIONAL ASSOCIATION, as Collateral Trustee for the Secured Parties (in such capacities, the “Collateral Trustee”), in favor of ACTIENT PHARMACEUTICALS LLC (“Actient”), ASTORA WOMEN’S HEALTH LLC (“Astora”), AUXILIUM PHARMACEUTICALS, LLC (“Auxilium Pharmaceuticals”), AUXILIUM US HOLDINGS, LLC (“Auxilium US”), BIOSPECIFICS TECHNOLOGIES CORP. (“Biospecifics Corp.”), BIOSPECIFICS TECHNOLOGIES LLC (“Biospecifics LLC”), DAVA INTERNATIONAL, LLC (“Dava”), DAVA PHARMACEUTICALS, LLC (“Dava Pharmaceuticals”), ENDO PHARMACEUTICALS INC. (“Endo Pharmaceuticals”), ENDO PHARMACEUTICALS SOLUTIONS INC. (formerly known as INDEVUS PHARMACEUTICALS, INC.) (“Endo Pharmaceuticals Solutions”), GENERICS BIDCO I, LLC (“Generics Bidco”), GENERICS INTERNATIONAL (US), INC. (“Generics International”), PAR PHARMACEUTICAL, INC. (“Par”), PAR PHARMACEUTICAL COMPANIES, INC. (“Par Companies”), PAR STERILE PRODUCTS, LLC (formerly known as JHP PHARMACEUTICALS, LLC) (“Par Sterile Products”), QUARTZ SPECIALTY PHARMACEUTICALS, LLC (“Quartz”), SLATE PHARMACEUTICALS, LLC (“Slate”), and VINTAGE PHARMACEUTICALS, LLC (“Vintage”) (each a “Grantor,” and collectively the “Grantors”). All capitalized terms used herein and not otherwise defined herein shall have the meaning assigned to such terms (directly or by reference) in the 2L US Security Agreement or applicable IP Security Agreement (each as defined below), as applicable.

WHEREAS, the Grantors, certain Domestic Subsidiaries of Parent and the Collateral Trustee entered into a Second Lien US Pledge and Security Agreement dated as of June 16, 2020 (as amended, restated, supplemented or otherwise modified from time to time, the “2L US Security Agreement”);

WHEREAS, pursuant to the 2L US Security Agreement, Actient, Auxilium Pharmaceuticals, Auxilium US, Dava, Dava Pharmaceuticals, Endo Pharmaceuticals, Endo Pharmaceuticals Solutions, Generics Bidco, Generics International, Par, Par Companies, Quartz, Slate and Vintage entered into a Confirmatory Grant of Security Interest in United States Trademarks, dated June 16, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2020 Trademark Security Agreement”), in favor of the Collateral Trustee, which was recorded with the United States Patent and Trademark Office (“USPTO”) on December 20, 2021 at Reel/Frame 7510/0430;

WHEREAS, pursuant to the 2L US Security Agreement, Astora, Endo Pharmaceuticals Solutions, Endo Pharmaceuticals and Par entered into a Confirmatory Grant of Security Interest in United States Patents, dated June 16, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2020 Patent Security Agreement”), in favor of the Collateral Trustee, which was recorded with the USPTO on September 17, 2021 at Reel/Frame 57538/0978;

WHEREAS, pursuant to the 2L US Security Agreement, Endo Pharmaceuticals and Par entered into a Confirmatory Grant of Security Interest in United States Trademarks, dated March 29, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from

time to time, the “2021 Trademark Security Agreement” (together with the 2020 Trademark Security Agreement, the “Trademark Security Agreements”), in favor of the Collateral Trustee, which was recorded with the USPTO on April 6, 2021 at Reel/Frame 7247/0581;

WHEREAS, pursuant to the 2L US Security Agreement, Endo Pharmaceuticals, Generics Bidco and Par Companies entered into a Confirmatory Grant of Security Interest in United States Copyrights, dated June 16, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2020 Copyright Security Agreement”), in favor of the Collateral Trustee, which was recorded with the United States Copyright Office (“USCO”) on September 22, 2021 at Volume/Document V9996D782;

WHEREAS, pursuant to the 2L US Security Agreement, Biospecifics Corp. entered into a Supplement to Confirmatory Grant of Security Interest in United States Patents, dated December 11, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2020 Supplement Patent Security Agreement”), in favor of the Collateral Trustee, which was recorded with the USPTO on December 14, 2020 at Reel/Frame 54751/0412;

WHEREAS, pursuant to the 2L US Security Agreement, Biospecifics LLC, Par, Auxilium US, Astora, Endo Pharmaceuticals Solutions and Endo Pharmaceuticals entered into a Confirmatory Grant of Security Interest in United States Patents, dated March 29, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2021 Patent Security Agreement” (together with the 2020 Patent Security Agreement and the 2020 Supplement Patent Security Agreement, the “Patent Security Agreements”), in favor of the Collateral Trustee, which was recorded with the USPTO on April 6, 2021 at Reel/Frame 55846/0246;

WHEREAS, pursuant to the 2L US Security Agreement, Par Sterile Products, Endo Pharmaceuticals and Endo Pharmaceuticals Solutions entered into a Confirmatory Grant of Security Interest in United States Copyrights, dated March 29, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “2021 Copyright Security Agreement” (together with the 2020 Copyright Security Agreement, the “Copyright Security Agreements”), in favor of the Collateral Trustee, which was recorded with the USCO on April 8, 2021 at Volume/Document V9992D769;

WHEREAS, pursuant to the 2L US Security Agreement and the Trademark Security Agreements, each Grantor party thereto pledged and granted to the Collateral Trustee, on behalf of and for the benefit of the Secured Parties, a security interest in (other than applications for trademarks or service marks filed in the USPTO or any successor office thereto on the basis of any such Grantor’s intent-to-use such trademark or service mark, prior to the filing of an amendment with the USPTO under 15 U.S.C. §1051(c) that brings the application into conformity with 15 U.S.C. §1051(a) or the filing of a verified statement of use with the USPTO under 15 U.S.C. §1051(d) that has been examined and accepted by the USPTO) all of such Grantor’s right, title and interest, wherever located and whether then owned or thereafter acquired (the “Trademark Security Interest”), in and to (collectively, the “Released Trademark Collateral”):

(1) such Grantor's trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof, including the goodwill of the business symbolized by the foregoing (collectively, "Trademarks"), including the Trademarks listed in Schedule I attached hereto (under the applicable Reel/Frame number);

(2) all renewals of the foregoing;

(3) all income, royalties, damages, claims and payments then or thereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements and dilutions thereof;

(4) all rights to sue for past, present, and future infringements and dilutions of the foregoing, including the right to settle suits involving claims and demands for royalties owing; and

(5) all rights corresponding to any of the foregoing throughout the world;

WHEREAS, pursuant to the 2L US Security Agreement and the Patent Security Agreements, each Grantor party thereto pledged and granted to the Collateral Trustee, on behalf of and for the benefit of the Secured Parties, a security interest in all of such Grantor's right, title and interest, wherever located and whether then owned or thereafter acquired (the "Patent Security Interest"), in and to (collectively, the "Released Patent Collateral");

(1) any and all patents and patent applications ("Patents"), including the Patents listed in Schedule II attached hereto (under the applicable Reel/Frame number);

(2) all inventions and improvements described and claimed therein;

(3) all reissues, divisionals, continuations, renewals, extensions, and continuations-in-part thereof;

(4) all income, royalties, damages, claims, and payments then or thereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof;

(5) all rights to sue for past, present, and future infringements thereof; and

(6) all rights corresponding to any of the foregoing throughout the world;

WHEREAS, pursuant to the 2L US Security Agreement and the Copyright Security Agreements, each Grantor party thereto pledged and granted to the Collateral Trustee, on behalf of and for the benefit of the Secured Parties, a security interest in all of such Grantor's right, title and interest, wherever located and whether then owned or thereafter acquired (the "Copyright Security Interest"), in and to (collectively, the "Released Copyright Collateral");



(1) all copyrights, rights and interests in copyrights, works protectable by copyright, copyright registrations, and copyright applications (“Copyrights”), including the Copyrights listed in Schedule III attached hereto (under the applicable Volume/Document number);

(2) all extensions of any of the foregoing;

(3) all income, royalties, damages, claims and payments now or hereafter due and/or payable under any of the foregoing, including, without limitation, damages or payments for past or future infringements for any of the foregoing;

(4) the right to sue for past, present, and future infringements of any of the foregoing; and

(5) all rights corresponding to any of the foregoing throughout the world; and

WHEREAS, the Collateral Trustee, without recourse, representation or warranty of any kind (express or implied), has agreed to release and fully discharge its security interest, including the Trademark Security Interest, Patent Security Interest and Copyright Security Interest (collectively, the “Security Interests”), in and to the respective Released Trademark Collateral, Released Patent Collateral and Released Copyright Collateral (collectively, the “Released IP Collateral”) that was granted pursuant to the 2L US Security Agreement and respective Trademark Security Agreements, Patent Security Agreements, and Copyright Security Agreements (collectively, the “IP Security Agreements”).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Trustee hereby agrees as follows:

SECTION 1. Release of Grant of Security. The Collateral Trustee, without any recourse, representation, warranty or other assurance of any kind, hereby (i) terminates and cancels the IP Security Agreements, (ii) releases and fully discharges its Security Interests in (and any other of its right, title and interest in and to) the Released IP Collateral that was pledged, assigned or granted to it pursuant to the IP Security Agreements or 2L US Security Agreement, as applicable, and (iii) re-assigns to each applicable Grantor any right, title or interest it may have in or to the Released IP Collateral of such Grantor.

SECTION 2. Recordation. The Collateral Trustee authorizes and requests, at the Grantors’ sole cost and expense, and without recourse, representation or warranty of any kind (express or implied), that the Commissioner for Trademarks of the United States Patent and Trademark Office, the Commissioner for Patents of the United States Patent and Trademark office, the Register of Copyrights of the United States Copyright Office, and any other applicable government officer record this Release.


SECTION 3. Execution. Delivery of an executed signature page of this Release by email or other electronic means (including in “.pdf” or “.tif” format) shall be as effective as delivery of a manually executed signature page of this Release.

SECTION 4. Governing Law. THIS RELEASE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

[REST OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Collateral Trustee has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

WILMINGTON TRUST, NATIONAL  
ASSOCIATION,  
as Collateral Trustee

By:   
Name: Andrew Lennon  
Title: Assistant Vice President

[Signature Page to Release of Security Interest in IP]

**TRADEMARK**  
**REEL: 008410 FRAME: 0301**

SCHEDULE I  
RELEASED TRADEMARK COLLATERAL

Reel/Frame 7510/0430

Trademark	App. No.	App. Date	Reg. No.	Reg. Date
ENDO AESTHETICS	88/429,700	May 14, 2019		
ENDO AESTHETICS	88/514,666	Jul 15, 2019		
FABBLIS	88/273,566	Jan 23, 2019		
MH ENDO MEN'S HEALTH Logo	88/310,155	Feb 21, 2019		
ELGANCI	88/194,136	Nov 14, 2018		
ENDO	88/346,651	Mar 19, 2019		
ENDO & E Design	88/346,714	Mar 19, 2019		
ACCUSURE	74/447,751	Oct 18, 1993	1902162	Jun 27, 1995
ACTIENT	77/684,171	Mar 5, 2009	4392463	Aug 27, 2013
ACTIENT	77/983,129	Mar 5, 2009	4165007	Jun 26, 2012
ACTIENT PHARMACEUTICALS	77/684,190	Mar 5, 2009	4392464	Aug 27, 2013
ADRENALIN	71/011,909	Aug 22, 1905	53934	Jun 12, 1906
APLISOL	72/379,567	Dec 28, 1970	925391	Dec 14, 1971
AUXILIUM ADVANTAGE	86/377,183	Aug 26, 2014	4746799	Jun 2, 2015
AUXILIUM ADVANTAGE COMMITTED TO ACCESS & Design	86/377,210	Aug 26, 2014	4746800	Jun 2, 2015
AVEED	85/791,387	Nov 30, 2012	4538915	May 27, 2014
AVEED and Design	86/488,946	Dec 23, 2014	4794099	Aug 18, 2015

Trademark	App. No.	App. Date	Reg. No.	Reg. Date
BARIACTIV	86/214,843	Mar 7, 2014	4634338	Nov 4, 2014
BOCA PHARMACAL	78/862,085	Apr 14, 2006	3290763	Sep 11, 2007
BOCA PHARMACAL & Design	78/862,093	Apr 14, 2006	3290764	Sep 11, 2007
BREVITAL	72/082,247	Sep 28, 1959	695950	Apr 12, 1960
CAPOTEN	73/164,605	Apr 3, 1978	1106489	Nov 21, 1978
CHERATUSSIN	77/470,478	May 9, 2008	3556687	Jan 6, 2009
COLY-MYCIN	72/082,457	Sep 30, 1959	699294	Jun 14, 1960
CYCLAFEM	78/789,496	Jan 11, 2006	4932639	Apr 5, 2016
CYCLAFEM 1/35	77/118,770	Feb 28, 2007	4932634	Apr 5, 2016
CYCLAFEM 7/7/7	78/789,508	Jan 11, 2006	4932640	Apr 5, 2016
D & Design	78/464,254	Aug 9, 2004	3051773	Jan 24, 2006
D DAVA & Design	78/462,577	Aug 5, 2004	3160114	Oct 17, 2006
DANTRIUM	72/387,314	Mar 24, 1971	937430	Jul 11, 1972
DANTRIUM	73/418,728	Mar 24, 1983	1277831	May 15, 1984
DANTRIUM	85/892,501	Apr 2, 2013	4432295	Nov 12, 2013
DAVA PHARMACEUTICALS INC.	78/778,968	Dec 22, 2005	3250845	Jun 12, 2007
DELATESTRYL	71/649,803	Jul 3, 1953	0589157	Apr 27, 1954
DELESTROGEN	71/677,901	Dec 7, 1954	619356	Jan 17, 1956
DILATRATE	73/225,986	Aug 3, 1979	1151441	Apr 21, 1981
DOSE PACK & Design	76/524,877	Jun 16, 2003	2916949	Jan 11, 2005

Trademark	App. No.	App. Date	Reg. No.	Reg. Date
DOUBLE SWOOSH Design	78/405,584	Apr 21, 2004	3225564	Apr 3, 2007
E & Lower Case Letter "e" Design	88/388,296	Apr 16, 2019	5986237	Feb 11, 2020
E (Stylized) (Endo Pathways Logo)	85/710,054	Aug 22, 2012	4552362	Jun 17, 2014
E Design (Endo Logo)	85/549,621	Feb 22, 2012	4347658	Jun 4, 2013
E ENDO & Design	85/498,455	Dec 19, 2011	4653200	Dec 9, 2014
EDEX	75/089,727	Apr 17, 1996	2177234	Jul 28, 1998
ELGANTISS	88/194,020	Nov 14, 2018	5825245	Aug 6, 2019
EMOQUETTE	77/590,803	Oct 10, 2008	3998554	Jul 19, 2011
ENDO	74/464,554	Dec 1, 1993	2004648	Oct 1, 1996
ENDO	85/549,674	Feb 22, 2012	4605917	Sep 16, 2014
ENDO	86/775,932	Oct 2, 2015	5307112	Oct 10, 2017
ENDO & Design	76/453,299	Sep 25, 2002	2921176	Jan 25, 2005
ENDO (Stylized #1)	71/360,540	Jan 22, 1935	0324936	Jun 4, 1935
ENDO (Stylized #2)	75/431,737	Feb 10, 1998	2189503	Sep 15, 1998
ENDO ADVANTAGE	86/903,528	Feb 10, 2016	5131687	Jan 31, 2017
ENDO ADVANTAGE & Design	86/903,552	Feb 10, 2016	5149307	Feb 28, 2017
ENDO GENERIC PRODUCTS	75/347,955	Aug 27, 1997	2267677	Aug 3, 1999
ENDO LABORATORIES	75/347,956	Aug 27, 1997	2317044	Feb 8, 2000
ENDOCET	74/519,259	Apr 22, 1994	1993892	Aug 13, 1996
ENDODAN	74/519,256	Apr 22, 1994	1995948	Aug 20, 1996

Trademark	App. No.	App. Date	Reg. No.	Reg. Date
ESTRAPEL	73/132,008	Jun 27, 1977	1089033	Apr 11, 1978
FABLYSE	88/194,104	Nov 14, 2018	5842986	Aug 27, 2019
FORTESTA	77/821,931	Sep 8, 2009	3951680	Apr 26, 2011
FORTESTA (TESTOSTERONE) GEL CIII & Design #2	85/432,595	Sep 27, 2011	4153422	Jun 5, 2012
GASTRO ADVANCED	88/253,350	Jan 8, 2019	5783950	Jun 18, 2019
GASTRO ADVANCED	88/253,350	Jan 8, 2019	5783950	Jun 18, 2019
GASTRODOSE & Design	77/278,904	Sep 13, 2007	3850437	Sep 21, 2010
GILDAGIA	85/227,432	Jan 27, 2011	4309564	Mar 26, 2013
GILDESS	77/576,973	Sep 23, 2008	3681267	Sep 8, 2009
GILDESS FE	77/694,864	Mar 19, 2009	4070985	Dec 13, 2011
IBUDONE	77/379,188	Jan 24, 2008	3551524	Dec 23, 2008
JHP PHARMACEUTICALS	77/339,615	Nov 29, 2007	3825570	Jul 27, 2010
JHP PHARMACEUTICALS	77/977,348	Nov 29, 2007	3670912	Aug 18, 2009
JHP PHARMACEUTICALS	85/479,160	Nov 22, 2011	4471366	Jan 21, 2014
KETALAR	72/276,388	Jul 20, 1967	840783	Dec 19, 1967
KIMIDESS	86/338,570	Jul 16, 2014	4814357	Sep 15, 2015
LEVATOL	73/558,642	Sep 16, 1985	1392091	May 6, 1986
LIDODERM	76/487,897	Feb 6, 2003	2870973	Aug 10, 2004
LIDODERM	73/790,107	Mar 30, 1989	1597110	May 22, 1990

Trademark	App. No.	App. Date	Reg. No.	Reg. Date
LIDODERM & Design	76/522,165	Jun 12, 2003	2853072	Jun 15, 2004
LUXARELLE	88/194,064	Nov 14, 2018	5825247	Aug 6, 2019
MEPERITAB	75/864,676	Dec 6, 1999	2502945	Oct 30, 2001
MEPROZINE	74/371,597	Mar 25, 1993	1903348	Jul 4, 1995
MOBAN	72/363,906	Jun 29, 1970	921439	Oct 5, 1971
MYZILRA	85/227,501	Jan 27, 2011	4250620	Nov 27, 2012
NASCOBAL	75/194,046	Nov 6, 1996	2157683	May 12, 1998
NASCOBAL NUTRITION DIRECT	86/559,235	Mar 10, 2015	5187043	Apr 18, 2017
NUBAIN	73/082,855	Apr 5, 1976	1062047	Mar 29, 1977
NUMORPHAN	74/494,055	Feb 24, 1994	1936442	Nov 21, 1995
ONCE YEARLY SUPPRELIN LA (HISTRELIN ACETATE) SUBCUTANEOUS IMPLANT & Design	85/354,181	Jun 23, 2011	4105047	Feb 28, 2012
OPANA	76/478,457	Dec 20, 2002	3060635	Feb 21, 2006
ORSYTHIA	77/705,981	Apr 3, 2009	4026539	Sep 13, 2011
PAR	86/182,802	Feb 3, 2014	4687174	Feb 17, 2015
PAR FORMULATIONS	85/681,233	Jul 19, 2012	4647341	Dec 2, 2014
PAR PATIENT ASSISTANCE RESOURCE	87/535,509	Jul 20, 2017	5439848	Apr 3, 2018
PAR PATIENT ASSISTANCE RESOURCE & Design	87/535,591	Jul 20, 2017	5439849	Apr 3, 2018
PAR PHARMACEUTICAL & Design	78/405,599	Apr 21, 2004	3118058	Jul 18, 2006



Trademark	App. No.	App. Date	Reg. No.	Reg. Date
PAR STERILE PRODUCTS	86/224,003	Mar 18, 2014	4725175	Apr 21, 2015
PAR STERILE PRODUCTS & Design	86/463,066	Nov 24, 2014	4807093	Sep 8, 2015
PERCOCET	73/072,165	Dec 18, 1975	1051682	Nov 2, 1976
PERCODAN	71/553,092	Mar 26, 1948	507983	Mar 22, 1949
PIN-X	73/825,517		1685013	May 5, 1992
PITOCIN	71/274,724	Nov 2, 1928	254956	Apr 2, 1929
PITRESSIN	71/274,727	Nov 2, 1928	254507	Mar 26, 1929
PREVIFEM	78/181,495	Nov 4, 2002	2872678	Aug 10, 2004
QUALITEST	75/882,595	Dec 27, 1999	2499673	Oct 23, 2001
QUALITEST & Design	85/354,137	Jun 23, 2011	4108182	Mar 6, 2012
QUALITEST PHARMACEUTICALS (Stylized)	111,182	Sep 12, 2008	111182	Sep 12, 2008
QUALITEST PHARMACEUTICALS (Stylized)	111,183	Sep 12, 2008	111183	Sep 12, 2008
QUALITEST PHARMACEUTICALS (Stylized)	111,181	Sep 12, 2008	111181	Sep 12, 2008
QUESTRAN	72/203,317	Oct 5, 1964	791696	Jun 29, 1965
R (Stylized)	76/524,876	Jun 16, 2003	2887378	Sep 21, 2004
RHEUMATREX	73/546,097	Jul 2, 1985	1404578	Aug 12, 1986
SEMPREX	78/429,596	Jun 3, 2004	3023249	Dec 6, 2005
STRIANT	76/442,855	Aug 19, 2002	2795914	Dec 16, 2003

Trademark	App. No.	App. Date	Reg. No.	Reg. Date
SULFAZINE	76/116,106	Aug 24, 2000	2595594	Jul 16, 2002
SUMYCIN	87/637,821	Oct 9, 2017	5746490	May 7, 2019
SUPPRELIN	74/004,595	Nov 22, 1989	1638851	Mar 26, 1991
TESTIM	76/310,800	Sep 7, 2001	2767622	Sep 23, 2003
TESTIM 1% (TESTOSTERONE GEL) III (Stylized)	76/653,201	Jan 6, 2006	3190743	Jan 2, 2007
TESTOPEL	73/132,009	Jun 27, 1977	1089034	Apr 11, 1978
THIO-24	73/369,262	Jun 14, 1982	1259784	Dec 6, 1983
THIS TIME HE WAS READY	86/459,962	Nov 20, 2014	4909786	Mar 1, 2016
TRIOSTAT	74/192,885	Aug 7, 1991	1915772	Aug 29, 1995
TRI-PREVIFEM	78/181,501	Nov 4, 2002	2872679	Aug 10, 2004
VALSTAR	77/332,945	Nov 19, 2007	3740487	Jan 19, 2010
VANTAS	76/522,929	Jun 17, 2003	2929415	Mar 1, 2005
VASOSTRICT	85/914,777	Apr 25, 2013	4660355	Dec 23, 2014
VIA PROJECT & Design	86/247,222	Apr 9, 2014	4648524	Dec 2, 2014
VINTAGE	74/642,219	Mar 6, 1995	1994771	Aug 20, 1996
VINTAGE PHARMACEUTICALS, LLC	77/884,070	Dec 2, 2009	3807004	Jun 22, 2010
VINTAGE PHARMACEUTICALS, LLC	77/879,984	Nov 24, 2009	3806991	Jun 22, 2010
VI-Q-TUSS	77/472,685	May 13, 2008	4030236	Sep 27, 2011
VOSPIRE	78/155,635	Aug 19, 2002	2837320	Apr 27, 2004

<b>Trademark</b>	<b>App. No.</b>	<b>App. Date</b>	<b>Reg. No.</b>	<b>Reg. Date</b>
VOSPIRE ER	78/155,642	Aug 19, 2002	2902246	Nov 9, 2004
ZYDONE	73/588,206	Mar 17, 1986	1412979	Oct 14, 1986
AUXILIUM	76/975,483	Aug 15, 2000	2754314	Aug 19, 2003
AUXILIUM & Design	76/673,677	Mar 5, 2007	3333304	Nov 13, 2007
TIMERX (Stylized #1)	74/137,028	Feb 7, 1991	1920597	Sep 19, 1995

Reel/Frame 7247/0581

	Trademark	App. No.	App. Date	Reg. No.	Reg. Date	Status	Owner
1.	ENDO THERAPEUTICS & Design	90/552,384	Mar 1, 2021	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
2.	ENDO THERAPEUTICS & Design	90/550,232	Feb 26, 2021	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
3.	Design Only	90/079,215	Jul 28, 2020	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
4.	ENDO & Design	90/079,225	Jul 28, 2020	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
5.	ESR	90/168,104	Sep 9, 2020	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
6.	REALLY CELLULITE	90/452,258	Jan 7, 2021	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
7.	ENZYMATIC SUBCISION AND REMODELING (ESR)	90/168,428	Sep 9, 2020	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
8.	ENZYMATIC SUBCISION AND REMODELING	90/168,379	Sep 9, 2020	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
9.	AN ENDO INTERNATIONAL COMPANY	79/303,244	Nov 17, 2020	n/a	n/a	Pending	Endo Pharmaceuticals Inc.
10.	ENDO	86/775,932	Oct 2, 2015	5307112	Oct 10, 2017	Registered	Endo Pharmaceuticals Inc.
11.	TRUDELIVERY	88/911,832	May 12, 2020	n/a	n/a	Pending	Par Pharmaceutical, Inc.

SCHEDULE II  
RELEASED PATENT COLLATERAL

Reel/Frame 57538/0978

Title	App. No.	App. Date	Patent No.	Issue Date
Implantable Article and Method	14/967730	12/14/2015		
Pelvic Health Implants and Methods	14/257475	04/21/2014		
Surgical Articles and Methods	15/384,946	12/20/2016		
Systems and Methods for Treating a Pelvic Disorder	15/099912	04/15/2016	10,201,412	02/12/2019
System and Methods for Treating a Pelvic Disorder	16/253,208	01/21/2019		
Apparatus for Treating Incontinence Stress and Urge	11/418790	05/05/2006	8195296	06/05/2012
Control of Urge Incontinence	09/806970	07/20/2001	6652449	11/25/2003
Control of Urge Incontinence	10/671144	09/24/2003	7582053	09/01/2009
Devices, Methods and Systems for Shrinking Tissues	10/866052	06/10/2004	7689290	03/30/2010
Devices, Methods and Systems for Shrinking Tissues	09/598076	06/20/2000	6587731	07/01/2003
Devices, Methods, and Systems for Shrinking Tissues	10/463976	06/17/2003	7483755	01/27/2009
Electrically Heated/Phase Change Probe Temperature Control	10/768778	01/30/2004	7476242	01/13/2009
Electrode Sling for Treating Stress & Urge Incontinence	12/281075	02/22/2007	9889298	02/13/2018
Endo-Pelvic Fascia Penetrating Heating Systems and Methods for Incontinence Treatment	11/040815	01/21/2005	7536225	05/19/2009
Endopelvic Fascia Treatment for Incontinence	09/413100	10/06/1999	6292700	09/18/2001
Energy Induced Bulking and Buttressing of Tissue for Incontinence	10/827887	04/19/2004	7167757	01/23/2007
Energy Induced Bulking and Buttressing of Tissues for Incontinence	10/828027	04/19/2004	7317949	01/08/2008
Handle for a Surgical Instrument	29/195937	12/18/2003	D543626	05/29/2007
Heating Method for Tissue Contraction	10/102596	03/19/2002	6882885	04/19/2005
Heating Method for Tissue Contraction	11/069681	03/01/2005	7792589	09/07/2010
Heating Method for Tissue Contraction	10/768780	01/30/2004	7251531	07/31/2007
Implantable Article and Method	09/939282	08/24/2001	6592515	07/15/2003
Implantable Article and Method	10/431719	05/08/2003	6884212	04/26/2005
Implantable Article and Method	10/873472	06/22/2004	7517313	04/14/2009
Implantable Article and Method	11/983412	11/07/2007	8057382	11/15/2011
Implantable Article and Method	13/252324	10/04/2011	8702586	04/22/2014
Implantable Article and Method	13/873983	04/30/2013	8905912	12/09/2014
Implantable Article and Method	14/169586	01/31/2014	9022921	05/05/2015
Implantable Article and Method	14/532576	11/04/2014	9211177	12/15/2015
Implantable Article and Method for the Treatment of Incontinence.	11/166277	06/27/2005	7762942	07/27/2010
Implantable Article and Method for Treating Urinary Incontinence Using Means for Repositioning the Implantable Article	09/917562	07/27/2001	6652450	11/25/2003
Implantable Article for Treatment of Urinary Incontinence	10/616925	07/11/2003	7083568	08/01/2006
Improved Pelvic Health Implants and Methods	11/983430	11/07/2007	8777836	07/15/2014
Incontinence Treatment Device	10/999824	11/30/2004	7387603	06/17/2008
Incontinence Treatment Device (fecal)	12/138031	06/12/2008	8340786	12/25/2012
Incontinence Treatment with Urethral Guide	09/991368	11/20/2001	6685623	02/03/2004
Incontinence Treatment with Urethral Guide	10/798717	03/10/2004	7179219	02/20/2007
Interspersed Heating/Cooling to Shrink Tissues for Incontinence	09/636795	08/11/2000	6572639	06/03/2003
Kit for Levator Avulsion Repair	12/594408	10/02/2009	8550980	10/08/2013
Low Power Consumption Implantable Pressure Sensor	10/076869	02/15/2002	6712772	03/30/2004

Title	App. No.	App. Date	Patent No.	Issue Date
Mechanical and Electrical Sensing For Incontinence Treatment	10/047135	01/15/2002	6896651	05/24/2005
Method and Apparatus for Correction of Urinary and Gynecological Pathologies, Including Treatment of Incontinence Cystocele	10/423662	04/25/2003	7407480	08/05/2008
Method and Apparatus for Cystocele Repair	10/840646	05/07/2004	7351197	04/01/2008
Method and Apparatus for Cystocele Repair	12/059117	03/31/2008	7993261	08/09/2011
Method and Apparatus for Treating Pelvic Organ Prolapse	12/321546	01/22/2009	8211005	07/03/2012
Method and Apparatus for Treating Pelvic Organ Prolapse	10/834943	04/30/2004	7500945	03/10/2009
Method for Supporting Vaginal Cuff	13/023652	02/09/2011	8636643	01/28/2014
Method for Supporting Vaginal Cuff	14/164462	01/27/2014	9,763,764	09/19/2017
Method for Supporting Vaginal Cuff	11/243802	10/05/2005	7901346	03/08/2011
Methods and Apparatus for Correction of Urinary and Gynecological Pathologies, Including Treatment of Male Incontinence and Female Cystocele	13/429947	03/26/2012	8684909	04/01/2014
Methods and Apparatus for Correction of Urinary and Gynecological Pathologies, Including Treatment of Male Incontinence and Female Cystocele	10/625199	07/23/2003	7608036	10/27/2009
Methods and Apparatus for Correction of Urinary and Gynecological Pathologies, Including Treatment of Male Incontinence and Female Cystocele	12/346080	12/30/2008	8162814	04/24/2012
Methods and Systems for Treatment of Prolapse	14/025988	09/13/2013	9060839	06/23/2015
Methods and Systems for Treatment of Prolapse	14/743259	06/18/2015	9283064	03/15/2016
Methods and Systems for Treatment of Prolapse	11/989256	02/24/2009	8535217	09/17/2013
Multi-Leveled Transgluteal Tension-Free Levatorplasty for Treatment of Rectocele	13/614012	09/13/2012	9149351	10/06/2015
Multi-Leveled Transgluteal Tension-Free Levatorplasty for Treatment of Rectocele	12/087552	07/09/2008	8585577	11/19/2013
Needle Deployment for Temperature Sensing from an Electrode	10/211973	08/01/2002	6852110	02/08/2005
Noninvasive Devices and Method for Shrinking of Tissues	09/651435	08/30/2000	6546934	04/15/2003
NonInvasive Devices, Methods and Systems for Shrinking of Tissues	09/765923	01/19/2001	6558381	05/06/2003
Noninvasive Devices, Methods and Systems for Shrinking of Tissues	09/768985	01/23/2001	6629535	10/07/2003
Non-Surgical Incontinence Treatment System and Method	10/759732	01/15/2004	7315762	01/01/2008
Pelvic Disorder Treatment	12/486492	06/17/2009	8083663	12/27/2011
Pelvic Disorder Treatment Device	10/497397	03/23/2005	7613516	11/03/2009
Pelvic Disorder Treatment Device	09/996668	11/29/2001	6862480	03/01/2005
Pelvic Floor Implant System and Method of Assembly	10/335119	12/31/2002	7229453	06/12/2007
Pelvic Floor Implant System and Method of Assembly	11/755422	05/30/2007	9,717,580	08/01/2017
Pelvic Health Implants and Methods	11/981597	10/31/2007	8702585	04/22/2014
Prolapse Repair	12/021092	01/28/2008	8038594	10/18/2011
Prolapse Repair	10/804718	03/19/2004	7347812	03/25/2008
Prolapse Repair	13/235694	09/19/2011	8753260	06/17/2014
Prolapse Repair	14/306135	06/16/2014	9339366	05/17/2016
Ribbed Electrodes and Methods for Their Use	09/925501	10/23/2000	6533780	03/18/2003

Title	App. No.	App. Date	Patent No.	Issue Date
Ribbed Electrodes and Methods for Their Use	10/351245	01/23/2003	7004942	02/28/2006
Sling Adjustment and Tensioning Accessory	09/968239	10/01/2001	6702827	03/09/2004
Sling Assembly with Secure and Convenient Attachment	09/990108	11/21/2001	6641525	11/04/2003
Sling Assembly with Secure and Convenient Attachment	10/616938	07/11/2003	7112171	09/26/2006
Sling Assembly with Secure and Convenient Attachment	11/535018	09/25/2006	7972262	07/05/2011
Sling Assembly with Secure and Convenient Attachment	13/115311	05/25/2011	8784295	07/22/2014
Sling Delivery System and Method of Use	09/917443	07/27/2001	6612977	09/02/2003
Sling Delivery System and Method of Use	10/280341	10/25/2002	6971986	12/06/2005
Sling Delivery System and Method of Use	11/203136	08/15/2005	7867161	01/11/2011
Sling Delivery System and Method of Use	12/984422	01/04/2011	8475357	07/02/2013
Sling Delivery System and Method of Use	13/903474	05/28/2013	8852077	10/07/2014
Surgical Article and Methods for Treating Female Urinary Incontinence	10/645588	08/22/2003	7303525	12/04/2007
Surgical Articles & Methods	10/280945	10/25/2002	7048682	05/23/2006
Surgical Articles & Methods	10/675816	09/30/2003	7291104	11/06/2007
Surgical Articles and Methods	11/202315	08/12/2005	8864646	10/21/2014
Surgical Articles and Methods	14/497892	09/26/2014	9,554,884	01/31/2017
Surgical Implants and Related Methods	11/115655	04/26/2005	7722527	05/25/2010
Surgical Implants and Related Methods	12/473747	05/28/2009	8109866	02/07/2012
Surgical Instrument and Method	09/917445	07/27/2001	6802807	10/12/2004
Surgical Instrument and Method	10/616926	07/11/2003	7267645	09/11/2007
Surgical Instruments	11/414484	05/01/2006	7223229	05/29/2007
Surgical Instruments for Addressing Pelvic Disorders	10/274524	10/17/2002	7037255	05/02/2006
Systems and Methods using Vasoconstriction for Improved Treatment of Tissues	10/029000	12/20/2001	6840954	01/11/2005
Systems, Apparatus, and Associated Methods for Needleless Delivery of Therapeutic Fluids	13/919073	06/17/2013	9,706,900	07/18/2017
Systems, Apparatus, and Associated Methods for Needleless Delivery of Therapeutic Fluids	11/942,080	11/19/2007	8491525	07/23/2013
Transobturator Surgical Articles and Methods	10/306179	11/27/2002	7070556	07/04/2006
Transobturator Surgical Articles and Methods	11/245364	10/05/2005	7988615	08/02/2011
Transobturator Surgical Articles and Methods	10/377101	03/03/2003	6911003	06/28/2005
Transobturator Surgical Articles and Methods	11/064875	02/24/2005	7686760	03/30/2010
Transobturator Surgical Articles and Methods	13/236287	09/19/2011	8864648	10/21/2014
Transobturator Surgical Articles and Methods	14/518159	10/20/2014	9433487	09/06/2016
Transobturator Surgical Articles and Methods	10/739668	12/18/2003	7357773	04/15/2008
Urinary Incontinence Diagnostic System	09/851662	05/08/2001	6579266	06/17/2003
Combination Treatment For Bladder Cancer	12/397,831	03/04/2009	8,273,721	09/25/2012
Compositions and Methods for Treating Precocious Puberty	11/155,822	06/17/2005	8,062,652	11/22/2011
Compositions and Methods for Treating Precocious Puberty	16/002,578	06/07/2018		
Controlled Release Formulations of Octreotide	11/372,749	03/10/2006	7,452,868	11/18/2008
Controlled Release Formulations of Octreotide	12/240,690	09/29/2008	7,803,773	09/28/2010
Controlled Release Formulations of Octreotide	15/246,020	08/24/2016		
Controlled Release Formulations of Octreotide	16/548,682	08/22/2019		
Controlled Release Formulations of Octreotide	12/814,293	06/11/2010	8,507,432	08/13/2013
Implantable Device for the Delivery of Octreotide and Methods for Use Thereof	16/456,601	06/28/2019		
Crystalline, Anhydrous Forms of Oxymorphone Hydrochloride	14/613,421	02/04/2015	9,440,986	09/13/2016
Crystalline, Anhydrous Forms of Oxymorphone Hydrochloride	15/263,175	09/12/2016	9,926,328	03/27/2018

<b>Title</b>	<b>App. No.</b>	<b>App. Date</b>	<b>Patent No.</b>	<b>Issue Date</b>
Crystalline, Anhydrous Forms of Oxymorphone Hydrochloride	14/091,399	05/24/2012	8,969,368	03/03/2015
Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery	10/787,385	02/26/2004	7,229,636	06/12/2007
Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery	10/814,399	03/31/2004	7,404,489	07/29/2008
Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery	12/079,875	03/27/2008	7,879,349	02/01/2011
Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery	12/142,240	06/19/2008	8,003,353	08/23/2011
Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery	13/189,061	07/22/2011	8,940,714	01/27/2015
Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery	14/485,228	09/12/2014	9,415,007	08/16/2016
Delayed Release Dosage Forms	10/943,356	09/17/2004	8,389,008	03/05/2013
Delivery of Dry Formulation of Octreotide	12/171,999	07/11/2008	7,759,312	07/20/2010
Delivery of Dry Formulation of Octreotide	15/246,009	08/24/2016		
Delivery Vehicle Composition and Methods for Delivery Antigens and Other Drugs	09/888,235	06/22/2001	7,767,197	08/03/2010
Implantable Device for the Delivery of Naltrexone and Methods of Use Thereof	13/155,257	06/07/2011		
Implanting Device	29/179382	04/09/2003	D492995	07/13/2004
Implanting Device and Method of Using Same	10/406,397	04/03/2003	7,214,206	05/08/2007
Intradermal-Penetration Agents for Topical Local Anesthetic Administration	09/523,652	03/10/2000	6,455,066	09/24/2002
Intradermal-Penetration Agents for Topical Local Anesthetic Administration	10/201,901	07/25/2002	6,746,689	06/08/2004
Method of Forming Adhesive Patch for Applying Medication to the Skin	09/629,783	07/31/2000	6,361,790	03/26/2002
Method of Inserting an Object Under the Skin	11/531,311	09/13/2006	7,510,549	03/31/2009
Method of Inserting an Object Under the Skin	12/415,681	03/31/2009	7,850,639	12/14/2010
Method of Manufacturing an Implant Device	13/897,895	05/20/2013	9,072,786	07/07/2015
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment	12/716,973	03/03/2010	8,808,737	08/19/2014
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Dosing for Renal Impairment	14/336,753	07/21/2014	9,789,103	10/17/2017
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Dosing for Renal Impairment	15/785,080	10/16/2017		
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol	11/766,748	06/21/2007		
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol	12/203,758	09/03/2008		
Method of Treating Pain Utilizing Extended-Release Formulations of Oxymorphone	11/742,956	05/01/2007		
Method of Using Oxymorphone Compositions for Treatment of Pain in Patients with Renal Impairment	11/766,740	06/21/2007		



Title	App. No.	App. Date	Patent No.	Issue Date
Methods for Use of Delivery Composition for Expanding, Activating, Committing or Mobilizing One or More Pluripotent, Self-Renewing and Committed Stem Cells	09/893,372	06/26/2001	6,649,189	11/18/2003
Octreotide Implant Having a Release Agent	12/490,979	06/24/2009	7,960,335	06/14/2011
Octreotide Implant Having a Release Agent	13/098,138	04/29/2011	8,383,577	02/26/2013
Oxymorphone Controlled Release Compositions	16/049,390	07/30/2018		
Oxymorphone Controlled Release Compositions	10/190,192	07/03/2002	9,820,982	11/21/2017
Oxymorphone Controlled Release Compositions	11/425,966	06/22/2006		
Oxymorphone Controlled Release Compositions	11/427,438	06/29/2006	8,329,216	12/11/2012
Oxymorphone Controlled Release Compositions	11/680,432	02/28/2007	8,309,122	11/13/2012
Oxymorphone Controlled Release Formulations	12/167,859	07/03/2008		
Particulate Drug-Containing Products and Method of Manufacture	10/717,429	11/19/2003	7,125,566	10/24/2006
Particulate Insulin-Containing Products and Method of Manufacture	09/740,573	12/18/2000	6,669,960	12/30/2003
Sequential Benzylic Oxidations of the Naloxone Ring System	09/520,099	03/07/2000	6,166,211	12/26/2000
Sustained Delivery of Exenatide and other Peptides	12/490,971	06/24/2009	8,071,537	12/06/2011
Sustained Delivery of Exenatide and other Peptides	12/844,357	07/27/2010	8,475,820	07/02/2013
Sustained Release Formulation of Nalbuphine	13/773,136	02/21/2013	8,765,175	07/01/2014
Sustained Release Formulation of Nalbuphine	14/290,413	05/29/2014	9,351,938	05/31/2016
Sustained Release Formulation of Nalbuphine	14/319,833	06/30/2014	9,186,330	11/17/2015
Sustained Release Formulation of Nalbuphine	15/162,062	05/23/2016		
Sustained Release Formulation of Nalbuphine	15/658,234	07/24/2017		
Sustained Release Formulations of Metformin	10/630,239	07/30/2003	7,214,387	05/08/2007
Sustained Release Formulations of Nalbuphine	11/509,347	08/24/2006	8,771,732	07/08/2014
Sustained Release Formulations of Nalbuphine	12/154,496	05/23/2008	8,394,812	03/12/2013
Sustained Release Formulations of Oxymorphone	10/189,932	07/03/2002	7,276,250	10/02/2007
Sustained Release Matrix Systems for Highly Soluble Drugs	11/729,024	03/27/2007	8,679,535	03/25/2014
Vitamin B12 Nasal Spray and Method of Use	12/618,099	11/13/2009	9,186,374	11/17/2015
Vitamin B12 Nasal Spray and Method of Use	14/738,417	06/12/2015	10,251,908	04/09/2019
Vitamin B12 Nasal Spray and Method of Use	14/878,430	10/08/2015	10,052,344	08/21/2018
Epinephrine Formulations	14/657,990	03/13/2015	9,119,876	09/01/2015
Epinephrine Formulations	16/258,204	01/25/2019		
Epinephrine Formulations	14/818,121	08/04/2015	9,295,657	03/29/2016
Epinephrine Formulations	14/863,112	09/23/2015	10,130,592	11/20/2018
Epinephrine Formulations	15/969,500	05/02/2018		
Flocculated Suspension of Megestrol Acetate	09/757,261	01/09/2001	6,593,318	07/15/2003
Flocculated Suspension of Megestrol Acetate	10/136,823	04/30/2002	6,593,320	07/15/2003
Nasal Calcitonin Formulations Containing Chlorobutanol	10/805,788	03/22/2004	7,812,120	10/12/2010
Nasal Calcitonin Formulations Containing Chlorobutanol	12/878,936	09/09/2010	8,138,149	03/20/2012
Nasal Calcitonin Formulations Containing Chlorobutanol	13/371,037	02/10/2012	8,486,891	07/16/2013
Process for Preparing Flutamide Compounds and Compounds Prepared by such Processes	09/685,443	10/11/2000	6,228,401	05/08/2001
Vasopressin Formulations for Use in Treatment of Hypotension	15/289,640	10/10/2016	9,687,526	06/27/2017

<b>Title</b>	<b>App. No.</b>	<b>App. Date</b>	<b>Patent No.</b>	<b>Issue Date</b>
Vasopressin Formulations for Use in Treatment of Hypotension	15/426,693	02/07/2017	9,744,209	08/29/2017
Vasopressin Formulations for Use in Treatment of Hypotension	15/426,703	02/07/2017	9,750,785	09/05/2017
Vasopressin Formulations for Use in Treatment of Hypotension	15/606,442	05/26/2017	9,937,223	04/10/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/612,649	06/02/2017	9,925,233	03/27/2018
Vasopressin Formulations for Use in Treatment of Hypotension	14/717,877	05/20/2015	9,744,239	08/29/2017
Vasopressin Formulations for Use in Treatment of Hypotension	14/717,882	05/20/2015	9,375,478	06/28/2016
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,305	08/28/2017	9,981,006	05/29/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,314	08/28/2017	9,962,422	05/08/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,322	08/28/2017	9,974,827	05/22/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,326	08/28/2017	10/010,575	07/03/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,330	08/28/2017	9,925,234	03/27/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,334	08/28/2017	9,993,520	06/12/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,336	08/28/2017	9,968,649	05/15/2018
Vasopressin Formulations for Use in Treatment of Hypotension	15/688,338	08/28/2017	9,919,026	03/20/2018
Vasopressin Formulations for Use in Treatment of Hypotension	16/291,796	03/04/2019		
Vasopressin Formulations for Use in Treatment of Hypotension	16/291,915	03/04/2019		
Vasopressin Formulations for Use in Treatment of Hypotension	16/161,277	10/17/2018		
Vasopressin Formulations for Use in Treatment of Hypotension	16/359,659	03/20/2019		
Epinephrine Formulations	16/817,253	03/12/2020		

Reel/Frame 54751/0412

<u>COUNTRY</u>	<u>TITLE</u>	<u>REG. (APP.) NO.</u>	<u>REG. (APP.) DATE</u>	<u>OWNERSHIP</u>
US	Compositions and methods for producing clostridial collagenases	10,119,131	11/6/2018	BioSpecifics Technologies Corp.
US	Compositions and methods for producing clostridial collagenases	(16/180,156)	11/5/2018	BioSpecifics Technologies Corp.
US	Compositions and methods for producing clostridial collagenases	(17/004,857)	8/27/2020	BioSpecifics Technologies Corp.
US	Treating method and product for uterine fibroids using purified collagenase	9,744,138	8/29/2017	Co-owned by BioSpecifics Technologies Corp., Duke University and North Carolina Central University
US	Treating method and product for uterine fibroids using purified collagenase	10,369,110	8/6/2019	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Treating method and product for uterine fibroids using purified collagenase	(15/666,365)	(8/1/2017)	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Treating method and product for uterine fibroids using purified collagenase	(16/506,435)	(7/9/2019)	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Treating method and product for uterine fibroids using purified collagenase	(17/769,197)	(10/6/2020)	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Thermosensitive Hydrogel Collagen use Formulations	(14/853,245)	(9/14/2016)	BioSpecifics Technologies Corp.
US	Thermosensitive Hydrogel Collagenase Formulations	10,272,140	4/30/2019	BioSpecifics Technologies Corp.
US	Treatment of Uterine Fibroids using Purified Collagenase	(62/915,360)	10/15/2019	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Treatment of Uterine Fibroids using Purified Collagenase	(62/915,363)	10/15/2019	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Treatment of Uterine Fibroids using Purified Collagenase	(62/915,367)	10/15/2019	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Treatment of Uterine Fibroids using Purified Collagenase	(17/070,747)	10/14/2020	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Thermosensitive Hydrogel Collagenase Formulations	(63/092,290)	10/15/2020	BioSpecifics Technologies Corp., North Carolina State University and Duke University

Reel/Frame 55846/0246

	<b>Title</b>	<b>App. No.</b>	<b>App. Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Status</b>	<b>Owner</b>
1.	Treatment of Uterine Fibroids using Purified Collagenase	62/915,360	10/15/2019			Provisional Filed	BioSpecifics Technologies LLC, The Johns Hopkins University and Duke University
2.	Treatment of Uterine Fibroids using Purified Collagenase	62/915,363	10/15/2019			Provisional Filed	BioSpecifics Technologies LLC, The Johns Hopkins University and Duke University
3.	Treatment of Uterine Fibroids using Purified Collagenase	62/915,367	10/15/2019			Provisional Filed	BioSpecifics Technologies LLC, The Johns Hopkins University and Duke University
4.	Treatment of Uterine Fibroids using Purified Collagenase	17/070,747	10/14/2020			Filed	BioSpecifics Technologies LLC, The Johns Hopkins University and Duke University
5.	Thermosensitive Hydrogel Collagenase Formulations	63/092,190	10/15/2020			Provisional Filed	BioSpecifics Technologies LLC, North Carolina State University and Duke University
6.	Epinephrine Formulations	16/817,253	03/12/2020			Filed	Par Pharmaceutical, Inc.
7.	Process for the Preparation of a Hot-melt Extruded Laminate	12/294,372	03/22/2007	8,465,759	06/18/2013	Granted	Auxilium US Holdings, LLC
8.	Stabilized Compositions Containing Alkaline Labile Drugs	13/463,375	05/03/2012	8,883,187	11/11/2014	Granted	Auxilium US Holdings, LLC
9.	Stabilized Compositions Containing Alkaline Labile Drugs	15/159,285	05/19/2016	9,867,786	01/16/2018	Granted	Auxilium US Holdings, LLC
10.	Methods and Apparatus for Correction of Urinary and Gynecological Pathologies, Including Treatment of Male Incontinence, and Female Cystocele	10/625,199	07/23/2003	7,608,036	10/27/2009	Granted	Astora Women's Health, LLC
11.	Use of Pagoclone for the Treatment of Social Anxiety Disorder	11/352,286	02/13/2006	7,553,847	06/30/2009	Granted	Endo Pharmaceuticals Solutions Inc.
12.	Selective Nerve Fiber Stimulation for Treating Heart Conditions	10/205,475	07/24/2002	7,778,703	08/17/2010	Granted	Astora Women's Health, LLC; Medtronic, Inc.
13.	System for Osmotic Delivery of Pharmaceutically Active Agents	09/872,173	06/01/2001	6,838,093	01/04/2005	Granted	Endo Pharmaceuticals Solutions Inc. (as exclusive licensee); Supernus

	Title	App. No.	App. Date	Patent No.	Issue Date	Status	Owner
							Pharmaceuticals, Inc. (as owner)
14.	Methods for Making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone	10/400,780	03/27/2003	6,949,653	09/27/2005	Granted	Endo Pharmaceuticals Solutions Inc.
15.	Methods for Making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone	11/206,144	08/18/2005	7,057,047	06/06/2006	Granted	Endo Pharmaceuticals Solutions Inc.
16.	Methods and Compositions for Alleviating Stuttering	11/046,706	02/01/2005	7,858,638	12/28/2010	Granted	Endo Pharmaceuticals Solutions Inc.
17.	Methods and Compositions for Alleviating Stuttering	13/489,516	06/06/2012	8,618,127	12/31/2013	Granted	Endo Pharmaceuticals Solutions Inc.
18.	Compositions and Methods for Treating Precocious Puberty	16/793,391	02/18/2020			Filed	Endo Pharmaceuticals Solutions Inc.
19.	Delivery of Dry Formulations of Octreotide	16/564,922	09/09/2019			Filed	Endo Pharmaceuticals Solutions Inc.
20.	Controlled Release Formulations of Octreotide	16/942,309	07/29/2020			Filed	Endo Pharmaceuticals Solutions Inc.
21.	Sustained Release Formulations of Nalbuphine	16/198,143	11/21/2018	10,406,106	09/10/2019	Granted	Endo Pharmaceuticals Solutions Inc.
22.	Treatment of Xerostomia	11/605,983	11/29/2006	7,501,452	03/10/2009	Granted	Endo Pharmaceuticals, Inc.
23.	Implant Device Release Agents and Methods of Using Same	12/109,852	04/25/2008	9,120,249	09/01/2015	Granted	Endo Pharmaceuticals Solutions Inc.
24.	Sulfonic Acid and Aldehyde Polymers for the Treatment and Prevention of HPV	12/393,778	02/26/2009	8,604,086	12/10/2013	Granted	Endo Pharmaceuticals Solutions Inc.
25.	Use of Megestrol Acetate for Improving Heart Function and the Treatment of Heart Insufficiency	11/667,899	09/24/2007	8,383,612	02/26/2013	Granted	Par Pharmaceutical, Inc.
26.	System and Method for Sorting Data	11/150,614	06/10/2005	7,246,020	07/17/2007	Granted	Par Pharmaceutical, Inc.
27.	System and Method for Sorting Data	11/810,651	06/06/2007	7,552,020	06/23/2009	Granted	Par Pharmaceutical, Inc.
28.	System and Method for Sorting Data	12/466,135	05/14/2009	7,996,170	08/09/2011	Granted	Par Pharmaceutical, Inc.
29.	System and Method for Sorting Data	13/185,599	12/31/2013	8,620,596	07/19/2011	Granted	Par Pharmaceutical, Inc.
30.	Treatment Method and Product for Uterine Fibroids using Purified Collagenase	17/064,126	10/06/2020			Filed	Biospecifics Technologies LLC; Duke University
31.	Treatment Method and Product for Uterine Fibroids using Purified Collagenase	17/083,650	10/29/2020			Filed	Biospecifics Technologies LLC

	<b>Title</b>	<b>App. No.</b>	<b>App. Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Status</b>	<b>Owner</b>
32.	Method to Treat Hypotension Using Vasopressin in Certain Genotypes	17/070,103	10/14/2020	10,920,278	02/16/2021	Granted	Par Pharmaceutical, Inc.
33.	Method to Treat Hypotension Using Vasopressin in Certain Genotypes	16/932,351	07/17/2020	10,844,435	11/24/2020	Granted	Par Pharmaceutical, Inc.
34.	Oxymorphone Controlled Release Compositions	17/035,453	09/28/2020			Filed	Endo Pharmaceuticals Inc.
35.	Crystalline, Anhydrous Forms of Oxymorphone Hydrochloride	15/263,175	09/12/2016	9,926,328	03/27/2018	Granted	Endo Pharmaceuticals Inc.
36.	Vasopressin Formulations for Use in Treatment of Hypotension	15/426,693	02/07/2017	9,744,209	08/29/2017	Granted	Par Pharmaceutical, Inc.
37.	Vasopressin Formulations for Use in Treatment of Hypotension	15/426,703	02/07/2017	9,750,785	09/05/2017	Granted	Par Pharmaceutical, Inc.
38.	Vasopressin Formulations for Use in Treatment of Hypotension	15/606,442	05/26/2017	9,937,223	04/10/2018	Granted	Par Pharmaceutical, Inc.
39.	Vasopressin Formulations for Use in Treatment of Hypotension	15/612,649	06/02/2017	9,925,233	03/27/2018	Granted	Par Pharmaceutical, Inc.
40.	Implantable Article and Method	14/967,730	12/14/2015	9,987,113	06/05/2018	Granted	Astora Women's Health LLC
41.	Systems and Methods for Treating a Pelvic Disorder	15/099,912	04/15/2016	10,201,412	02/12/2019	Granted	Astora Women's Health LLC
42.	Sulfonic Acid and Aldehyde Polymers for the Treatment and Prevention of HPV	12/393,778	02/26/2009	8,604,086	12/10/2013	Granted	Endo Pharmaceuticals Solutions Inc.
43.	Systems, Apparatus, and Associated Methods for Needleless Delivery of Therapeutic Fluids	13/919073	06/17/2013	9706900	07/18/2017	Granted	Endo Pharmaceuticals, Inc.
44.	Systems, Apparatus, and Associated Methods for Needleless Delivery of Therapeutic Fluids	11/942,080	11/19/2007	8491525	07/23/2013	Granted	Endo Pharmaceuticals, Inc.
45.	Needleless Delivery Systems	13/569,788	08/08/2012	8,808,232	08/19/2014	Granted	Endo Pharmaceuticals, Inc.
46.	Injection Tube for Jet Injection Device	14/515,757	10/16/2014	9,814,837	11/14/2017	Granted	Endo Pharmaceuticals, Inc.
47.	Needleless Injection Device Components, Systems, and Methods	12/839,956	07/20/2010	8,366,657	02/05/2013	Granted	Endo Pharmaceuticals, Inc.
48.	Method and Apparatus for Compensating for Injection Media Viscosity in a Pressurized Drug Injection System	15/233,040	08/10/2016	9,795,733	10/24/2017	Granted	Endo Pharmaceuticals, Inc.

	<b>Title</b>	<b>App. No.</b>	<b>App. Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Status</b>	<b>Owner</b>
49.	Devices, Systems, and Methods for Delivering Fluid to Tissue	13/260,869	11/18/2011	8,628,494	01/14/2014	Granted	Endo Pharmaceuticals, Inc.
50.	Devices, Systems, and Methods for Delivering Fluid to Tissue	15/180,495	06/13/2016	9,675,759	06/13/2017	Granted	Endo Pharmaceuticals, Inc.
51.	High Pressure Delivery System and Method for Treating Pelvic Disorder Using Large Molecule Therapeutics	14/659,095	03/16/2015	9,827,375	11/28/2017	Granted	Endo Pharmaceuticals, Inc.
52.	Delayed Release Dosage Forms	10/943,356	09/17/2004	8,389,008	03/05/2013	Granted	Endo Pharmaceuticals Inc.
53.	Sustained Release Formulations of Metformin	10/630,239	07/30/2003	7,214,387	05/08/2007	Granted	Endo Pharmaceuticals Inc.
54.	Heating Method for Tissue Contraction	11/069,681	03/01/2005	7,792,589	09/07/2010	Granted	Astora Women's Health LLC

SCHEDULE III

RELEASED COPYRIGHT COLLATERAL

Volume/Document V9996D782

Copyrights

Copyright Title	Reg. No.	Reg. Date
OPANA ER PRESCRIPTION LABELS (December 2016)	TX0008390453	4/19/2017
PERCODAN Label (February 2006)	TX0008239282	1/11/2016
ENDO WEBSITE (SEPTEMBER 2015)	TX0005795256	4/27/2017
ENDO.COM Website (2018)	TX0008747814	10/26/2018
PROMETHAZINE VC WITH CODEINE SYRUP PRESCRIPTION LABEL (February 2013)	TX0008199021	2/18/2016
PERCOCET Medicine Labels (December 2016)	TX0008350726	12/16/2016
Clinical Considerations in Parenteral Analgesia	TX0001280669	2/2/1983
Endo Website September 2015.	TX0008257368	9/25/2015
Regulatory Affairs - eCTD Templates	Txu001666726	9/16/2008



**Volume/Document V9992D769**

	<b>Title</b>	<b>Registration Number</b>	<b>Registration Date</b>	<b>Status</b>	<b>Owner</b>
1.	Dantrium IV	PA0001690155	8/6/2010	Registered	PAR Sterile Products, LLC
2.	Dantrium Website (www.dantrium.com)	TX0007181883	6/28/2010	Registered	PAR Sterile Products, LLC
3.	Indevus urgency severity scale	TXu001081116	5/20/2003	Registered	Indevus Pharmaceuticals, Inc. (now known as Endo Pharmaceuticals Solutions, Inc.)
4.	PHOTONUMERIC CELLULITE SEVERITY SCALE - THIGH AND BUTT (October 2016)			Filed	Endo Pharmaceuticals Inc.